Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?

Most patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage of disease. Until recently, systemic treatment options that showed survival benefits in HCC have been limited to tyrosine kinase inhibitors, antibodies targeting oncogenic signaling pathways or VEGF receptors. The H...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hye Won, Cho, Kyung Joo, Park, Jun Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Immunologists 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049588/
https://www.ncbi.nlm.nih.gov/pubmed/32158599
http://dx.doi.org/10.4110/in.2020.20.e11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049588/
https://www.ncbi.nlm.nih.gov/pubmed/32158599
http://dx.doi.org/10.4110/in.2020.20.e11

Ejemplares similares